305 related articles for article (PubMed ID: 26424199)
21. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
22. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
Venkatakrishnan K; Pickard MD; von Moltke LL
Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246
[TBL] [Abstract][Full Text] [Related]
23. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Zhang H; Cui D; Wang B; Han YH; Balimane P; Yang Z; Sinz M; Rodrigues AD
Clin Pharmacokinet; 2007; 46(2):133-57. PubMed ID: 17253885
[TBL] [Abstract][Full Text] [Related]
25. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
26. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
[TBL] [Abstract][Full Text] [Related]
27. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
28. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
Yu H; Tweedie D
Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
[TBL] [Abstract][Full Text] [Related]
29. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
Backman JT; Filppula AM; Niemi M; Neuvonen PJ
Pharmacol Rev; 2016 Jan; 68(1):168-241. PubMed ID: 26721703
[TBL] [Abstract][Full Text] [Related]
30. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
Fan Y; Sun B; Agarwal S; Zhang L
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
Sinha V; Zhao P; Huang SM; Zineh I
Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
[TBL] [Abstract][Full Text] [Related]
32. Transporter biology in drug approval: regulatory aspects.
Maeda K; Sugiyama Y
Mol Aspects Med; 2013; 34(2-3):711-8. PubMed ID: 23506904
[TBL] [Abstract][Full Text] [Related]
33. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
[TBL] [Abstract][Full Text] [Related]
34. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
35. Dealing with the complex drug-drug interactions: towards mechanistic models.
Varma MV; Pang KS; Isoherranen N; Zhao P
Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
[TBL] [Abstract][Full Text] [Related]
36. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
37. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
Rodriguez-Monguio R; Seoane-Vazquez E
AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 Apr; 97(4):12-6. PubMed ID: 8008381
[TBL] [Abstract][Full Text] [Related]
39. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
[TBL] [Abstract][Full Text] [Related]
40. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo.
Zhou T; Arya V; Zhang L
J Clin Pharmacol; 2019 Aug; 59(8):1049-1060. PubMed ID: 30924955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]